P2RY12 and chronic kidney disease: In addition, an observational study (30) conducted in Canada on the use of DAPT in patients with ACS combined with CKD indicated that, compared to patients without CKD, those with CKD are less likely to receive potent P2Y12 inhibitors, have a shorter duration of DAPT treatment, and have a higher bleeding risk.